215 related articles for article (PubMed ID: 15049280)
1. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
Hachulla E
Rev Med Interne; 2004 Mar; 25(3):195-200. PubMed ID: 15049280
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
3. [Pulmonary arterial hypertension and systemic sclerosis].
Launay D; Humbert M; Hachulla E
Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
5. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
8. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
9. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
10. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
11. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
12. Role of iloprost and bosentan in pulmonary arterial hypertension.
Saleh JA
Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
[TBL] [Abstract][Full Text] [Related]
13. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
[TBL] [Abstract][Full Text] [Related]
14. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
17. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
18. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Oldfield V; Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
[TBL] [Abstract][Full Text] [Related]
19. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Cozzi F; Pigatto E; Rizzo M; Favaro M; Zanatta E; Cardarelli S; Riato L; Punzi L
Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
